Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy

Next Previous
Trial Profile

An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MVX ONCO 1 (Primary)
  • Indications Bladder cancer; Brain cancer; Carcinoma; Cervical cancer; Colon cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Sarcoma; Small cell lung cancer; Soft tissue sarcoma; Thyroid cancer; Uterine cancer
  • Focus Adverse reactions; First in man
  • Acronyms MVX-ONCO
  • Sponsors MaxiVax

Most Recent Events

  • 13 Sep 2022 Interim results assessing safety and efficacy of MVX-ONCO in advanced relapsing solid tumors presented at the 47th European Society for Medical Oncology Congress
  • 26 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2026.
  • 26 Jan 2022 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top